In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Long-term effects of cardiac rehabilitation in obese patients

Session Poster session 3

Speaker Marta Braga

Event : Heart Failure 2017

  • Topic : preventive cardiology
  • Sub-topic : Exercise Testing
  • Session type : Poster Session

Authors : M Braga (Porto,PT), A Rocha (Porto,PT), H Nascimento (Porto,PT), R Pinto (Porto,PT), G Pestana (Porto,PT), M Tavares-Silva (Porto,PT), A Nunes (Porto,PT), P Araujo (Porto,PT), V Araujo (Porto,PT), F Parada-Pereira (Porto,PT), MJ Maciel (Porto,PT)

M Braga1 , A Rocha1 , H Nascimento1 , R Pinto1 , G Pestana1 , M Tavares-Silva1 , A Nunes1 , P Araujo1 , V Araujo1 , F Parada-Pereira1 , MJ Maciel1 , 1Sao Joao Hospital - Porto - Portugal ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 490

Introduction: Cardiac rehabilitation programs (CRP) improves exercise capacity (EC) and decreases cardiovascular morbidity and mortality after an acute coronary syndrome (ACS). However, some subpopulations are under-represented in CRP, namely obese patients.

Purpose: To compare the EC of obese patients with non-obese patients over 12 months of follow-up after CRP.

Methods: We retrospectively analysed data prospectively collected from patients who underwent CRP after an ACS. Patients were divided in two groups according to their body mass index (BMI): BMI=30Kg/m2 (obese) and BMI<30kg/m2 (non-obese). EC was assessed with a standard exercise test, including chronotropic index, rate-pressure product, exercise duration, and intensity in metabolic equivalents (METs). EC was evaluated at baseline (T1), end of CRP (T2) and after 12 months of follow-up (T3). The mixed between-within analysis of variance was used to compare groups.

Results: Of a total 469 patients, 108 patients were obese. Except for diabetes and hypertension, there were no additional significant differences at baseline between obese and non-obese patients. Regarding EC, obese showed lower chronotropic index at all three moments (p<0.001), but improved at T2 and T3, like the non-obese group (T1- obese: 63.3±17.0% vs non-obese: 70.6±18.9%; T2- obese: 70.5±13.7% vs. non-obese: 76.6±17.2%; T3- obese: 74.9±16.7% vs non-obese: 77.6±17.7%, within-groups partial Eta square 0.176, p<0.001). The same results were seen regarding rate-pressure product (T1- obese: 20090±3660 mmHg*bpm vs non-obese: 20600±3910 mmHg*bpm; T2- obese: 22360±4050 mmHg*bpm vs. non-obese: 22410±3930 mmHg*bpm; T3- obese: 23100±4210 mmHg*bpm vs non-obese: 22780±4320 mmHg*bpm, within-groups partial Eta square 0.213, p<0.001). Both groups improved exercise duration and intensity between T1 and T2, showing a nonsignificant decline in T3 (duration: T1- obese: 7.5±2.1 min vs 8.7±2.2 min; T2- obese: 9.4±1.8 min vs non-obese: 10.6±2.0 min; T3- obese: 9.3±2.0 min vs non-obese: 10.4±2.3 min; intensity: T1- obese 7.8±1.9 METs vs non-obese: 9.2±2.2 METs; T2- obese: 9.4±1.8 METs vs. non-obese: 11.1±2.0 METs; T3- obese: 9.3±1.8 vs non-obese: 11.0±2.2 METs, within-groups partial Eta square 0.47 and 0.38 respectively, p<0.001). Between-groups comparison showed that non-obese patients achieved a greater duration and intensity than obese patients at all 3 moments (p<0.001).

Conclusions: Although EC of obese patients was inferior to non-obese patients, our study revealed that CRP significantly improved EC in this population and this benefit persisted after 12 months of follow-up. This data highlights the importance of a greater referral of obese patient to CRP.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are